心脏代谢表型与纤维化和代谢功能障碍相关的脂肪性肝病中的死亡率有关
Rui Dong1, Ting Tian2, Zhenghan Luo3
1Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing, China.
Nutrition, metabolism, and cardiovascular diseases : NMCD
|December 14, 2024
概括
在与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者中发现了三种不同的心脏代谢表型. 两个表型,OCHBP和SGLMD,显示出与晚期肝纤维化和增加全因死亡风险的显著关联.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 心脏病学 心脏病学
- 代谢综合征是代谢综合征的一种.
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 经常与多种心脏代谢风险因素同时发生.
- 了解MASLD中的特定心脏代谢表型对于风险分层和管理至关重要.
研究的目的:
- 在患有MASLD的患者中识别出不同的心脏代谢表型.
- 研究这些表型与晚期肝纤维化和全因死亡率的关联.
主要方法:
- 利用国家健康和营养检查调查 (NHANES) 数据的无监督集群分析.
- 鉴定并验证了三个不同的表型:MCMRF,OCHBP和SGLMD.
- 使用后勤和考克斯回归模型来评估与肝纤维化和死亡率的关联.
主要成果:
- 确定并复制了三种稳定的心脏代谢表型:轻度心脏代谢风险因子 (MCMRF),超重与高透气血压 (OCHBP) 结合,以及严重的葡萄糖和脂质代谢功能障碍 (SGLMD).
- OCHBP和SGLMD表型与晚期肝纤维化 (ORs从4.37到9.66) 的更高几率有显著的关联.
- 与MCMRF相比,OCHBP和SGLMD表型都显示出所有死因的风险增加 (HRs范围从1.39到2.51).
结论:
- 在MASLD患者中确定了三种异质心脏代谢表型.
- 这些表型与晚期肝纤维化和全因死亡率有显著的关联.
- 这些发现有可能在MASLD护理中推进精准医学方法.
相关概念视频
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...